Acumen Pharmaceuticals (NASDAQ:ABOS) Issues Earnings Results

Acumen Pharmaceuticals (NASDAQ:ABOS) released its earnings results on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.09, FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• ALTITUDE-AD readout late 2026 — Acumen expects full efficacy and safety results from its phase II sabirnetug study this year, which the company says will inform its late‑stage development strategy and the broader Aβ‑oligomer hypothesis in AD.
• Preclinical EBD progress and funding — non‑human primate data showed 14–40‑fold higher brain levels for EBD candidates versus native antibody, the profiles exceeded targets, and a recent $35.75 million private placement was raised to advance the program toward an IND targeted in mid‑2027.
• Supportive Phase Ib biomarker signals — in INTERCEPT‑AD sabirnetug produced early CSF improvements (notably phospho‑tau‑181 and neurogranin) after three doses, which management views as supportive for potential phase II efficacy.
• Limited near‑term cash runway and high 2025 losses — year‑end cash and marketable securities of $116.9 million are expected to fund operations only into early 2027, and the company reported a $121.3 million net loss in 2025, implying additional financing will likely be needed to fully execute longer‑term plans.

Acumen Pharmaceuticals Stock Up 1.3%

Shares of NASDAQ:ABOS traded up $0.03 during trading on Thursday, hitting $2.66. 193,692 shares of the company were exchanged, compared to its average volume of 851,872. The firm’s 50 day moving average price is $2.68 and its 200-day moving average price is $2.15. Acumen Pharmaceuticals has a 12-month low of $0.86 and a 12-month high of $3.60. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.02 and a quick ratio of 6.02. The stock has a market capitalization of $161.36 million, a P/E ratio of -1.19 and a beta of 0.21.

Insider Buying and Selling

In related news, CEO Daniel Joseph Oconnell sold 37,755 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $1.99, for a total value of $75,132.45. Following the completion of the sale, the chief executive officer directly owned 619,982 shares of the company’s stock, valued at $1,233,764.18. The trade was a 5.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have sold 149,818 shares of company stock worth $285,057. 9.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in Acumen Pharmaceuticals during the fourth quarter worth $105,000. Quadrature Capital Ltd purchased a new stake in Acumen Pharmaceuticals during the fourth quarter worth $103,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Acumen Pharmaceuticals in the 4th quarter worth about $47,000. Marshall Wace LLP purchased a new position in Acumen Pharmaceuticals during the 4th quarter valued at about $44,000. Finally, Dimensional Fund Advisors LP raised its position in Acumen Pharmaceuticals by 12.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 49,062 shares of the company’s stock worth $104,000 after acquiring an additional 5,538 shares during the last quarter. 71.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ABOS has been the subject of a number of recent research reports. BTIG Research raised their target price on Acumen Pharmaceuticals from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. Wall Street Zen lowered Acumen Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Acumen Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.